• Agreement Speeds Access to SARS-Cov-2 Antigen Test
    Alastair Smith
  • Mark Davies

News & Views

Agreement Speeds Access to SARS-Cov-2 Antigen Test

Feb 18 2021

A partnership which will accelerate Avacta’s AffiDX™ SARS-CoV-2 lateral flow rapid antigen test to market is enabling the test to be CE marked for professional use under Mologic’s existing ISO13485 quality system. The CE mark will then be transferred to Avacta when it receives ISO13485 accreditation, which is expected by the end of March 2021. AffiDX supports COVID-19 testing in low and middle income countries

The partnership immediately provided Avacta with additional manufacturing capacity through Mologic and its partners including Global Access Diagnostics (GAD), in addition to the scaled-up manufacturing capacity being built with BBI and Abingdon Health. Combined, these partnerships will deliver several millions of tests per month; Avacta is also continuing discussions with other manufacturers in the UK and overseas to access additional capacity to meet demand.

Clinical evaluation of the lateral flow test is currently being carried out at a hospital in mainland Europe and Avacta will shortly initiate further clinical validation studies in the UK and abroad.

Dr Alastair Smith, Chief Executive Officer of Avacta Group said: “I am very pleased to announce this partnership with Mologic, which follows a close collaboration over recent months. I am also delighted that this collaboration provides an opportunity for Avacta to support antigen testing in low and middle income countries through Mologic’s international manufacturing links. 

“The longer-term collaboration with Mologic, on a range of diagnostic tests, offers a significant potential opportunity for the Group. The combination our technologies to generate a world-leading second-generation antigen test for SARS-CoV-2 is an exciting possibility.”

Mark Davis, Chief Executive Officer of Mologic, said: “Mologic offers a highly versatile range of scientific and manufacturing services for the development of diagnostic technology. We are very pleased to be working with Avacta to apply our expertise in this important project and look forward to it paving the way for further collaborations.”


Digital Edition

International Labmate Buyers Guide 2022

June 2022

In This Edition Evaluation of Recovery of Basic Analytes Using a Mixed-Mode Strong Cation Exchange SPE Microplate by HPLC-MS The Benefits of SEC-MALLS in Biopharmaceutical Applications...

View all digital editions

Events

AACC Annual Meeting & Clinical Lab Expo

Jul 24 2022 Chicago, IL, USA

ICMGP 2022

Jul 24 2022 Virtual event

ACS National Meeting & Expo, Fall 2022

Aug 21 2022 Chicago, IL, USA & Online

ACHEMA 2022 - NEW DATES

Aug 22 2022 Frankfurt, Germany

IMSC 2022

Aug 27 2022 Maastricht, Netherlands

View all events